Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Markovic

Showing results (301-310 of 368) with videos related to

Pageof 37
Sort By:
Journal of Translational Medicine|August 17, 2006
Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanomaSvetomir N Markovic, Allan B Dietz, Carl W Greiner, et al.
Mayo Clinic Proceedings|February 1, 2016
Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic MelanomaMariah L White, Thomas D Atwell, A Nicholas Kurup, et al.
Cancer|August 24, 2012
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775Lisa A Kottschade, Vera J Suman, Domingo G Perez, et al.
British Journal of Haematology|August 8, 2006
Absolute lymphocyte count predicts overall survival in follicular lymphomasMustaqeem Siddiqui, Kay Ristow, Svetomir N Markovic, et al.
International Journal of Radiation Oncology, Biology, Physics|October 14, 2015
Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral ImmunotherapyMiran Blanchard, Kevin G Shim, Michael P Grams, et al.
JCI Insight|April 20, 2018
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapyYiyi Yan, Siyu Cao, Xin Liu, et al.
Frontiers in Bioscience (Elite Edition)|December 29, 2011
Fluctuation of systemic immunity in melanoma and implications for timing of therapyAlexey A Leontovich, Roxana S Dronca, Vera J Suman, et al.
Blood Cancer Journal|April 20, 2013
Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphomaL F Porrata, K M Ristow, T M Habermann, et al.
JCI Insight|May 17, 2016
T cell Bim levels reflect responses to anti-PD-1 cancer therapyRoxana S Dronca, Xin Liu, Susan M Harrington, et al.
Cancer|October 19, 2017
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanomaRobert R McWilliams, Jacob B Allred, Jessica A Slostad, et al.
Pageof 37

Showing results (301-310 of 368) with videos related to

Sort By:
Pageof 37
Journal of Translational Medicine|August 17, 2006
Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanomaSvetomir N Markovic, Allan B Dietz, Carl W Greiner, et al.
Mayo Clinic Proceedings|February 1, 2016
Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic MelanomaMariah L White, Thomas D Atwell, A Nicholas Kurup, et al.
Cancer|August 24, 2012
A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775Lisa A Kottschade, Vera J Suman, Domingo G Perez, et al.
British Journal of Haematology|August 8, 2006
Absolute lymphocyte count predicts overall survival in follicular lymphomasMustaqeem Siddiqui, Kay Ristow, Svetomir N Markovic, et al.
International Journal of Radiation Oncology, Biology, Physics|October 14, 2015
Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral ImmunotherapyMiran Blanchard, Kevin G Shim, Michael P Grams, et al.
JCI Insight|April 20, 2018
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapyYiyi Yan, Siyu Cao, Xin Liu, et al.
Frontiers in Bioscience (Elite Edition)|December 29, 2011
Fluctuation of systemic immunity in melanoma and implications for timing of therapyAlexey A Leontovich, Roxana S Dronca, Vera J Suman, et al.
Blood Cancer Journal|April 20, 2013
Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphomaL F Porrata, K M Ristow, T M Habermann, et al.
JCI Insight|May 17, 2016
T cell Bim levels reflect responses to anti-PD-1 cancer therapyRoxana S Dronca, Xin Liu, Susan M Harrington, et al.
Cancer|October 19, 2017
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanomaRobert R McWilliams, Jacob B Allred, Jessica A Slostad, et al.
Pageof 37